Skip to main content
  • FDA Approves Next-Gen TAVR Device

    Sapien 3 Ultra approved for intermediate and greater risk patients

    The FDA approved the latest generation Sapien 3 device, Ultra, for transcatheter aortic valve replacement (TAVR), Edwards Lifesciences announced.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details